TO THE EDITOR: The Imatinib Suspension and Validation (ISAV) study1 is a multicenter trial of imatinib discontinuation (ID) among patients with chronic myeloid leukemia (CML) in undetectable deep molecular remission (U-DMR). After 12 months of follow-up, 48% of patients relapsed (total n = 107), with the majority of relapses occurring within the first 9 months. An inverse relationship between patient age and risk of relapse was also observed at this timepoint. Here we report the final results of ISAV after a median follow-up of 49 months, as well as the dynamics of leukemic tumor load as determined by digital polymerase chain reaction (dPCR) in nonrelapsed patients. This trial is registered at www.clinicaltrials.gov (NCT01578213). Eligible patients were 18 years and older and had CML, either in chronic or accelerated phase, with U-DMR of at least 18 months’ duration and at least...

Diral, E., Mori, S., Antolini, L., Abruzzese, E., Le Coutre, P., Martino, B., et al. (2020). Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. BLOOD, 136(19), 2237-2240 [10.1182/BLOOD.2019004371].

Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation

Mori S.;Antolini L.;Fontana D.;Piazza R.;Gambacorti Passerini C.
Ultimo
2020

Abstract

TO THE EDITOR: The Imatinib Suspension and Validation (ISAV) study1 is a multicenter trial of imatinib discontinuation (ID) among patients with chronic myeloid leukemia (CML) in undetectable deep molecular remission (U-DMR). After 12 months of follow-up, 48% of patients relapsed (total n = 107), with the majority of relapses occurring within the first 9 months. An inverse relationship between patient age and risk of relapse was also observed at this timepoint. Here we report the final results of ISAV after a median follow-up of 49 months, as well as the dynamics of leukemic tumor load as determined by digital polymerase chain reaction (dPCR) in nonrelapsed patients. This trial is registered at www.clinicaltrials.gov (NCT01578213). Eligible patients were 18 years and older and had CML, either in chronic or accelerated phase, with U-DMR of at least 18 months’ duration and at least...
Lettera in rivista
Imatinib; discontinuation; chronic myeloid leukemia; clinical trial
English
9-giu-2020
2020
136
19
2237
2240
open
Diral, E., Mori, S., Antolini, L., Abruzzese, E., Le Coutre, P., Martino, B., et al. (2020). Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. BLOOD, 136(19), 2237-2240 [10.1182/BLOOD.2019004371].
File in questo prodotto:
File Dimensione Formato  
10281-315442_VoR.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 656.45 kB
Formato Adobe PDF
656.45 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/315442
Citazioni
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 14
Social impact